CPH 82 (Reumacon ) in refractory inflammatory arthritis

CPH 82 (Reumacon ) in refractory inflammatory arthritis

In this retrospective analysis of the DMARD CPH 82 in 44 Icelandic patients with severe refractory arthritis, clinical tolerance was good and serious side effects absent, although the majority were using the drug in combination with other DMARDS. Side effects leading to discontinuation were seen in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scandinavian journal of rheumatology 2000, Vol.29 (5), p.323-325
Hauptverfasser: GUDMUNDSDOTTIR, Elisabet S, JONSSON, Helgi
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Antirheumatic Agents - adverse effects
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Biological and medical sciences
Bones, joints and connective tissue. Antiinflammatory agents
Drug Therapy, Combination
Female
Glycosides - adverse effects
Glycosides - therapeutic use
Humans
Lignans - adverse effects
Lignans - therapeutic use
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Retrospective Studies
Time Factors
Treatment Failure
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In this retrospective analysis of the DMARD CPH 82 in 44 Icelandic patients with severe refractory arthritis, clinical tolerance was good and serious side effects absent, although the majority were using the drug in combination with other DMARDS. Side effects leading to discontinuation were seen in 16% and the three year drug-survival was 51%.
ISSN:0300-9742
1502-7732
DOI:10.1080/030097400447723